GLP1R
Glucagon-like peptide 1 receptor
As of the edition of 20 October 2026, GLP1R (glucagon-like peptide 1 receptor, UniProt P43220) has 25 drugs tested at it and 21 companies on the list, 5 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43220
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 80
- Disease areas
- Nutrition and metabolism; Hormones; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels; Digestive system; Immune system; Nervous system
- Registered trials of its drugs
- 1,449
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 9 |
| Went quiet | 2 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 25 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Semaglutide | Marketed | Phase 4 | Ends 2034 |
| Liraglutide | Marketed | Phase 4 | Ended 2025 |
| Exenatide | Marketed | Phase 4 | Ended 2025 |
| Dulaglutide | Marketed | Phase 4 | Ended 2026 |
| Lixisenatide | Marketed | Phase 4 | Ends 2028 |
| Orforglipron | Marketed | Phase 4 | Ends 2037 |
| Avexitide | Stopped | Phase 4 | none listed |
| Retatrutide | Active | Phase 3 | none listed |
| Survodutide | Active | Phase 3 | none listed |
| Albiglutide | Marketed | Phase 4 | Ended 2026 |
| Cotadutide | Stopped | Phase 2 | none listed |
| Danuglipron | Stopped | Phase 2 | none listed |
12 of 25 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 3 |
| Engaged | 12 |
| Undetermined | 1 |
| Total on the list | 21 |
The other 18 companies at GLP1R
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at GLP1R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.